Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lexapro, Namenda Inventory Workdowns Cut Forest's Fourth Quarter Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

Wholesale inventory levels of the antidepressant Lexapro fell from 21 days at the end of 2004 to 15 days as of March 31, Forest says. Total prescription volume of the Alzheimer's agent Namenda increased, but sales were similarly negatively impacted by inventory workdowns, the company says.

You may also be interested in...



Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch

Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.

Forest To Use New Data To Promote Lexapro In Face Of Paxil CR Relaunch

Lexapro market share gain is behind expectations because of the market reentry of GlaxoSmithKline’s Paxil CR, increased detailing by antidepressant competitors and more aggressive promotion of generics by payors.

Antidepressant Market Will Remain Flat In Face Of Adult Suicidality Concerns, Forest Says

The impact of media attention on the adult suicide issue will be “hard to predict,” President & COO Goodman says. Forest expects FDA action on a Namenda supplemental NDA for mild-to-moderate Alzheimer’s in the next few weeks.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel